Drugs / Eicosapentanoic acid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00290056 | Nov 2005 → Nov 2009 | cardiac rhythm disease, coronary artery disorder | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00168987 | Jan 2005 → Nov 2006 | cholangiocarcinoma, colorectal neoplasm, hepatocellular carcinoma | Charite University, Berlin, Germany | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01661764 Comparator | Feb 2013 → Dec 2016 | adenomatous colon polyp | Vanderbilt University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04140201 Comparator | Feb → Jun 2020 | diabetic retinopathy | Alaa Hassan ElBaz | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eicosapentanoic acid | “Eicosapentanoic acid + standard treatment” NCT04140201 ↗ |
| Known as | EPA | “Eicosapentanoic acid (EPA) has been introduced as specific and anticatabolic acting substrate in cancer patients.” NCT00168987 ↗2“such as eicosapentanoic acid [EPA] and docosahexanoic acid [DHA] may reduce the risk of colorectal cancer.” NCT01661764 ↗ “Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).” NCT00290056 ↗ |
| Modality | Other / unclassified | “marine-derived n-3 polyunsaturated fatty acids [PUFA] such as eicosapentanoic acid [EPA] and docosahexanoic acid [DHA]” NCT01661764 ↗ |
| Route | Oral | “oral nutritional supplement rich in eicosapentanoic acid” NCT00168987 ↗ |